Stay updated on Pembrolizumab & Endocrine Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.

Latest updates to the Pembrolizumab & Endocrine Therapy Clinical Trial page
- Check7 days agoChange DetectedThe NCT02778685 record is displayed instead of an access-denied page, providing details about the trial of pembrolizumab with endocrine therapy and palbociclib for metastatic breast cancer. The record includes study design and eligibility information, outcome measures, published research, and study documents.SummaryDifference81%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The page continues to display a 403 error instead of the study record.SummaryDifference1%

- Check42 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the study page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing detailed study information with a generic error view. This removes access to the trial's key data and related materials on the page.SummaryDifference23%

- Check63 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a new version of the page documentation.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Endocrine Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.